Adaptive Biotechnologies Corporation (ADPT)
NASDAQ
Healthcare
Biotechnology
$17.62
▲ +0.92%
Market Cap
$2.82B
Sector
Healthcare
Industry
Biotechnology
Beta
2.15
52-Wk Range
9.955-20.76
CEO
Chad Robins
Country
US
Currency
USD
Adaptive Biotechnologies Corporation, founded in 2009 and headquartered in Seattle, Washington (operating as Adaptive TCR Corporation until its name change in December 2011), is a commercial-stage entity focused on pioneering an immune medicine platform. This advanced platform is engineered for the precise diagnosis and effective treatment of a broad spectrum of illnesses. The company offers several core technological solutions. Its immunoSEQ platform, a foundational immunosequencing product, is vital for translational research and discovering novel prognostic and diagnostic markers. For confi…
Open full interactive analysis & DCF →